New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
16:52 EDTAGN, SLXP, VRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
After Wall Street Journal reported that Allergan (AGN) approached Salix (SLXP) and at least one other company about a takeover, BMO Capital says it believes an all-cash deal or a cash deal and buyback in the $8B-$15B range would "significantly reduce any remaining probability" of a Valeant (VRX) hostile buyout. BMO believes an acquisition in the gastrointestinal space, which is Salix's focus, as well as neurology, oncology or rare diseases could make sense for Allergan. The firm has an Outperform rating on Allergan with a $230 price target.
News For AGN;VRX;SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use